S&P Futures
4,003.25 -4.00 (-0.10%) Dow Futures
32,624.00 -7.00 (-0.02%) Nasdaq Futures
12,766.25 -22.25 (-0.17%) Russell 2000 Futures
1,764.90 -2.40 (-0.14%) Crude Oil
73.43 +0.62 (+0.85%) Gold
1,954.70 +0.90 (+0.05%)
Sino Biopharmaceutical Limited (SMZ1.SG)
Chart Events
Performance Outlook
| Previous Close | 0.5096 |
| Open | 0.5026 |
| Bid | 0.5002 x 1111100 |
| Ask | 0.5160 x 1111100 |
| Day's Range | 0.5002 - 0.5026 |
| 52 Week Range | 0.4411 - 0.6496 |
| Volume | |
| Avg. Volume | 1,728 |
| Market Cap | 4.026B |
| Beta (5Y Monthly) | N/A |
| PE Ratio (TTM) | 15.16 |
| EPS (TTM) | N/A |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
- Reuters
China's CanSinoBIO H1 revenue drops on weaker COVID shot demand
China's CanSino Biologics reported a 69.5% drop in revenue for the first six months versus a year ago, joining global and domestic COVID-19 vaccine makers affected by waning demand for their shots. The decline from 2.06 billion yuan ($299.8 million) to 629.8 million yuan was mainly driven by weaker COVID vaccine demand as growth in global uptake slowed and price changes of CanSinoBIO's products, the firm said in a company filing published on Sunday. CanSinoBIO, which sells a one-dose shot in countries including China and Mexico and is seeking approval for an inhaled version of the vaccine, said half-year net profit dropped by 98.7% year-on-year.
- Zacks
F-star (FSTX) Stock Rises on Buyout Offer From Sino Biopharm
Sino Biopharmaceutical, through its wholly-owned subsidiary, is set to acquire F-star (FSTX) for $7.12 per share in cash. The transaction is likely to close by second-half 2022.
- Benzinga
F-star Therapeutics Shares Are Rallying Today - Read Why
invoX Pharma, a wholly-owned subsidiary of Sino Biopharmaceutical Limited, has agreed to acquire F-star Therapeutics Inc (NASDAQ: FSTX) for $7.12 per share. The proposed acquisition values F-star at approximately $161 million. Just a year ago, F-star priced its IPO at $7. F-star's next-generation tetravalent (2+2) bispecific antibody platform complements Sino Biopharma's existing capabilities and reinforces its global oncology pipeline. Four programs are progressing in the clinic, three based on
